Physician profile
Meredith Koomson
NPI 1447571294
$7,047.26
in general payments reported to CMS, 2019-2025
34 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $204 · 2021: $576 · 2022: $827 · 2023: $1,444 · 2024: $1,486 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,844 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,844.21 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $908.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $796.51 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $771.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $742.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $733.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $620.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.22 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $374.26 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $321.62 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $169.98 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $124.08 | 2019-2025 | Veozah |
| Medtronic, INC. | $120.18 | 2021-2024 | Mycarelink |
| Amgen INC. | $114.52 | 2019-2024 | Krystexxa |
| Horizon Therapeutics Plc | $87.29 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $63.41 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $62.11 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $59.28 | 2019 | |
| Sunovion Pharmaceuticals INC. | $55.65 | 2022 | |
| Merck Sharp & Dohme LLC | $55.34 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.48 | 2024-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $42.24 | 2019-2021 | |
| Corcept Therapeutics | $39.56 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $34.54 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.57 | 2022 | |
| Gilead Sciences, INC. | $23.50 | 2025 | |
| Sobi, INC | $23.29 | 2022 | |
| Ge Healthcare | $21.16 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $20.33 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.97 | 2020 | |
| Janssen Biotech, INC. | $16.56 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.14 | 2023 | |
| Dexcom, INC. | $14.49 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $8.42 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $6.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Koomson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.